IfPA analysis unearths the story hidden in the data – taking into account real world evidence and experiences.

Latest

ICER Misses the Numbers That Matter
Comments on ICER’s Draft Evidence Report: Modulator Treatments for Cystic Fibrosis
Comments on ICER’s Draft Evidence Report: Acute Treatment for Migraine
How ICER’s Evidence Report Fails Migraine Patients

2020

2019

2018

2017

2016

ICER Misses the Numbers That Matter
Comments on ICER’s Draft Evidence Report: Modulator Treatments for Cystic Fibrosis
Comments on ICER’s Draft Evidence Report: Acute Treatment for Migraine
How ICER’s Evidence Report Fails Migraine Patients
Video: What’s Wrong With ICER?
VIDEO: Why Health Care Providers Should Care About ICER
Comments on Draft Scoping Document for Modular Cystic Fibrosis Treatment
Can ICER Put a Value on Diabetes Management?
Comments on ICER’s Type 2 Diabetes Report
Comments on ICER’s 2020 Value Assessment Framework
Comments on Draft Scoping Document for Type 2 Diabetes Therapies
Comments on Draft Scoping Document for Rheumatoid Arthritis Therapies
A Study of the Qualitative Impact of Non-Medical Switching
Comments on Draft Evidence Report for Severe Asthma Therapies
Can ICER Put a Price on Asthma Control?
Comments on Draft Scoping Document for Severe Asthma Therapies
How Physicians View the 340B Drug Pricing Program
What’s Missing from ICER’s Analysis of Migraine Therapies?
Feedback on CGRP Inhibitors as Preventive Treatments for Patients with Migraine
ICER Case Study: Migraine
The ICER Myth
Medicare Physician Quality Reporting Initiative Fact Sheet
Comments on Draft Scoping Document for CGRP Inhibitors for Migraine Prevention
Input on ICER’s Upcoming Analysis of Erenumab as a Treatment for Migraine
What ICER’s Analysis of Tardive Dyskinesia Treatments Doesn’t Explain
Feedback on ICER’s Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value report
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical Switching
Cost-Motivated Treatment Changes & Non-Medical Switching: Commercial Health Plans Analysis
What’s Missing from ICER’s Assessment of Abuse-Deterrent Opioids
Feedback on ICER’s Abuse Deterrent Formulations of Opioids: Effectiveness and Value report
How ICER’s Missteps Leave Access in Doubt For Atopic Dermatitis Patients
Why ICER’s Model Doesn’t Work for Rheumatoid Arthritis Treatments
Cost-Motivated Treatment Changes: Implications for Non-Medical Switching
Feedback on ICER’s Psoriasis Draft Evidence Report
Cost-Motivated Treatment Changes in Medicare Part B: Implications for Non-Medical Switching
Feedback on ICER’s Value Framework